Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of VMX-C001 in healthy volunteers
NL-OMON58775Phase 1Completed
- Sponsor
- VarmX
- Start
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, single-arm trial of VMX-C001 in anticoagulant reversal and Bleeding, sponsored by VarmX. Primary endpoint: Primary endpoint(s). Started Feb 2024; status: completed.
02
Drugs
VMX-C001
03
Conditions
anticoagulant reversalBleeding
Beyond the preview
Go deeper on NL-OMON58775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58775.